Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study

Next Previous
Trial Profile

Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FIRE-6-Avelumab; FIRE-6-Avelumab study

Most Recent Events

  • 16 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 21 Nov 2023 This trial has been completed (End Date: 07 Aug 2023), according to European Clinical Trials Database record.
  • 13 Sep 2022 Primary endpoint of Progression free survival has not been met, according to results presented at the 47th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top